IACTA Pharmaceuticals
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
8024 4th St, Downey, California, 90241, ...Phone Number
(844) 422-8279Website
www.iactapharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About IACTA Pharmaceuticals
IACTA is an innovation leader in ophthalmic therapeutics, led by former top executives from one of the leading eye care companies in the world. The company currently has multiple products in development for major market opportunities. IC 800/805 is a novel, non-opioid, dual enkephalinase inhibitor (DENKI), being studied for the treatment of acute and chronic ocular pain. In addition, IACTA's IC 265, is a SYK kinase inhibitor being developed as a potential novel treatment for dry eye disease and other ocular indications. Solidified by management's world-class, proven R&D experience and supported by the company's IPAC subsidiary in Asia, IACTA is equipped to identify high-quality pharmaceutical technologies, create novel formulations, develop clinic-ready assets, and manage regulatory and intellectual property challenges to accelerate the development and commercialization of innovative NCEs.Explore more
IACTA Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is IACTA Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on IACTA Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once IACTA Pharmaceuticals has new funding data
Check out if IACTA Pharmaceuticals is spiking on competitors!
IACTA Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if IACTA Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at IACTA Pharmaceuticals
Click to see if IACTA Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when IACTA Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to IACTA Pharmaceuticals
Compare insights from companies similar to IACTA Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
IACTA Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
IACTA Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about IACTA Pharmaceuticals.
IACTA Pharmaceuticals Tech Stack
A closer look at the technologies used by IACTA Pharmaceuticals
See more technologies
IACTA Pharmaceuticals News & Media
IACTA Pharmaceuticals to Present at Jefferies Healthcare Conference
GUAYNABO, Puerto Rico--(BUSINESS WIRE)--IACTA Pharmaceuticals to Present at Jefferies Healthcare ConferenceIACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology
GUAYNABO, Puerto Rico & MONTREAL--(BUSINESS WIRE)--IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery TechnologyIACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury
GUAYNABO, Puerto Rico--(BUSINESS WIRE)--IACTA Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye InjuryIACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer
IRVINE, Calif.--(BUSINESS WIRE)--IACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding IACTA Pharmaceuticals
Sign Up For FreeTo access detailed company insights
IACTA is an innovation leader in ophthalmic therapeutics, led by former top executives from one of the leading eye care companies in the world. The company currently has multiple products in development for major market opportunities. IC 800/805 is a novel, non-opioid, dual enkephalinase inhibitor (DENKI), being studied for the treatment of acute a... Read More
